<DOC>
	<DOCNO>NCT01623531</DOCNO>
	<brief_summary>The aim study show first line treatment concentrate fibrinogen superiority conventional therapy fresh frozen plasma ( FFP ) , platelet , cryoprecipitate perioperative management bleeding complex cardiac surgery .</brief_summary>
	<brief_title>Prospective Double Blinded Randomized Control Study Use Fibrinogen High-Risk Cardiac Surgery</brief_title>
	<detailed_description>All patient recruit Queen Elizabeth II ( QEII ) Health Sciences Center , Halifax , Nova Scotia , sole tertiary cardiac surgical referral center Nova Scotia perform approximately 1000 open heart surgical procedure yearly , include 700 isolated coronary artery bypass graft ( CABG ) procedure . Inclusion criterion : All patient schedule elective complex cardiac surgical procedure include , double procedure ( aortic valve replacement+coronary artery bypass graft , mitral valve replacement+coronary artery bypass graft , aortic valve replacement+mitral valve replacement ) , redo-sternotomies , aortic root repair +/-aortic valve replacement . Exclusion criterion : Any known congenital preexist bleed disorder , preexist clinically significant abnormal fibrinogen level , severe liver disease ( alanine aminotransferase aspartate aminotransferase &gt; 150 U/l ) , inability providing informed consent , emergency surgery , pregnancy nursing , age 18 year , intake anti-platelet drug within last 2- 5 day surgery ( low dose aspirin allow ) allergy concentrate fibrinogen component product , anemia ( Hb &lt; 110 ) , diagnose deep venous thrombosis , pulmonary embolism , acute stroke acute myocardial infarction . The primary outcome : Cumulative perioperative amount ( number unit total volume ) blood component use start surgery 24 hour administration study drug placebo . 'Blood Components ' define fresh component blood ( RBCs , plasma , platelet , Cryo ) . The secondary outcome : Fibrinogen level , hematocrit , prothrombin time ( PT ) , partial prothrombin time ( PTT ) , INR , platelet count , Hemoglobin ( Hb ) , Thromboelastometry ( ROTEMÂ® , clot time ( CT ) , clot formation time ( CFT ) , Angle , maximum clot firmness ( MCF ) , Cardiovascular intensive care unit ( CVICU-stay ) , Hospital-stay , In-Hospital Mortality , Hemoglobin , adverse event ( anaphylaxis , stroke , myocardial infarction , pulmonary embolism , deep vein thromboembolism ) usage factor VII concentrate human prothrombin complex ( factor II , VII , IX , X ) , total avoidance transfusion cardiopulmonary bypass ( CPB ) 24h administration study drug placebo .</detailed_description>
	<criteria>All patient schedule elective complex cardiac surgical procedure include double procedure ( aortic valve replacement ( AVR ) +CABG , mitral valve repair/replacement ( MVR ) +CABG , AVR+MVR ) Redosternotomies Aortic root repair +/ AVR Any known congenital preexist bleed disorder preexist clinically significant abnormal fibrinogen level ( normal : 2.54.79g/l ) severe liver disease ( alanine aminotransferase aspartate aminotransferase &gt; 150 U/l ) inability provide inform consent emergency surgery pregnancy nursing age 18 year intake antiplatelet drug within2 5 day preoperatively ( low dose ASA allow ) allergy concentrate fibrinogen component product anemia ( Hgb &lt; 110 ) diagnose deep vein thrombosis ( DVT ) pulmonary embolism acute stroke acute myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fibrinogen</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>high risk</keyword>
	<keyword>cardiopulmonary bypass</keyword>
	<keyword>bleeding</keyword>
	<keyword>blood transfusion</keyword>
</DOC>